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ABSTRACT 
 
 
Carcinoma of unknown primary represents a heterogenous group of tumour with well known  
characteristics and behavior. It is essential to locate the primary tumor to facilitate specific 
treatment for patients. It is said that conventional investigations may detect the primary in 
about 30% of patients diagnosed with this condition. F-18- flurodeoxyglucose PET-CT has 
been used to detect the primary tumor when conventional methods fail. This study 
retrospectively investigates the role of F-18-flurodeoxyglucose in detection of primary in 
Carcinoma of Unknown Primary in Malaysia. We found that F-18-flurodeoxyglucose PET-
CT localised the primary in 40% of patients, has a sensitivity of 76.67%, specificity of 
92.11% and positive predictive value of 88.46%. The most common site of the primary is the 
lung, followed by the ovaries and the pancreas.  
 
 
 
 
 
 
 
 
 
 
 
 
 XIII 
ABSTRAK 
 
 
Carcinoma of unknown primary adalah satu kumpulan pelbagai tumor dengan sifat dan 
tingkahl aku yang telah diketahui. Adalah menjadi satu keperluan untuk mengesan lokasi 
utama kanser tersebut bagi memudahkan pemberian rawatan yang lebih berkesan dan khusus 
untuk pesakit.  Kajian yang telah dijalankan sebelum ini telah menunjukkan bahawa siasatan 
konvensional boleh mengesan kedudukan barah primer dalam kira-kira 30% daripada pesakit 
yang didiagnosis dengan keadaan ini. FDG PET-CT adalah salah satu lagi cara untuk 
mengesan barah apabila kaedah konvensional gagal. Kertas ini secara retrospektif menyiasat 
peranan FDG PET-CT dalam mengesan Carcinoma of unknown primary di Malaysia. Kami 
mendapati lokasi primer barah berhasil dikesan oleh FDG PET/CT di dalam 40 % daripada 
pesakit yang telah dirujuk. Ia adalah 76.67 % sensitif,  mempunyai kekhususan 92.11 % dan 
mempunyai nilai ramalan positif sebanyak 88.46 %.  Lokasi utama yang kerap di diagnosa 
adalah adalah paru-paru , diikuti oleh ovari dan pankreas. 
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CHAPTER ONE 
INTRODUCTION 
 
Carcinoma of Unknown Primary or commonly known as CUP is a heterogenous group of tumor 
which has metastasized from its primary site at the time of diagnosis. It occurs in 3-5% of 
patients diagnosed with cancer (Pavlidis et al 2003). Diagnosis is only made after tissue biopsy 
confirms the metastatic disease where conventional radiology, biochemical tumor markers, 
immunohistochemistry and endoscopies fail to identify the primary site, which the cancer 
originates from.  
 
The identification of primary site of the tumor of importance, as this will ensure definitive 
treatment to be given in tailoring treatment for patients. Detection and appropriate staging can 
often change management (Pelosi et al., 2006) and the course of disease (Raber et al., 1991 and 
Lenzi et al., 1997). Hence, identification of the primary site and staging is pertinent to further 
tailor treatment thus determining the management of patients, eventually determine the prognosis 
of patients. 
 
Majority of patients diagnosed with CUP has poor prognosis. Median survival for patients 
diagnosed with CUP said to be between 4 to 12 months (Altman et al., 1986, Raber et al., 1991, 
Lenzi et al., 1997 and Chorost et al. 2004). This is due to the tumour behaviour and also due to 
  
2 
the fact that majority will not respond to treatment. Half of the patients will succumb to the 
disease after 1 year and much less than that will be surviving 5 years after being diagnosed. 
Systemic chemotherapy may prolong survival up to 24 months, but it comes with severe side 
effect such as grade III/ IV myelosuppression (Raber et al., 1991). 
 
 Prior to being diagnosed with CUP, patients will be subjected to a lot of investigations in order 
to determine the primary. These are often costly and time consuming. Conventional 
investigations is said to identify the primary tumor in 27-40% of patients diagnosed with CUP 
(Le Chevalier et al., 1988 and Abbruzzese et al., 2009). However, even at autopsy about 50% of 
the primary sites are not identified (Le Chevalier et al. 1988 and Al-Brahim et al., 2005).  As 
time is of the essence for patients diagnosed with CUP, it is hoped that there is a diagnostic tool 
sensitive and specific that can be utilised to elicit the primary tumor. 
 
The use of positron emission tomography, PET coupled with computed tomography, CT utilizing 
F-18 Fluorodeoxyglucose, FDG a radioactive glucose analogue allows the evaluation of 
metabolic activity of cells instead of anatomical abnormalities detected by conventional 
radiology. This study is aimed to evaluate the role of positron emission tomography combined 
with computed tomography using F-18 Flurodeoxyglucose in patients diagnosed with carcinoma 
of unknown primary in Malaysia.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Definition of carcinoma of unknown primary 
Carcinoma of unknown primary, CUP is a group of heterogeneous tumor but with similar 
biological behaviour. Patients often present with variety of presentation, which is usually related 
to the metastatic site. Multiple sites or organs involvements are seen in more than 30-50% of 
these patients (Abbruzzese et al. 1994 and Briasoulis at al. 1997). Patients are often diagnosed 
with CUP after conventional radiology, biochemical tumor markers, immunohistochemistry and 
endoscopies are unsuccessful in attaining the tumor origin following tissue biopsy from the 
metastatic site. 
 
2.2 Epidemiology 
CUP accounts for 2.3% to 4.2% of all human cancer. It is the seventh to eight most common type 
of cancer and the fourth frequent cause of cancer related death, both in male and female in the 
world (Pavlidis and Fizazi, 2005). The overall age-standardised incidence per 100 000 people per 
year is 7-12 cases in USA and it occurs in 3-5% of all newly diagnosed cancer patients (Pavlidis 
and Fizazi, 2005). At presentation, median age is approximately 60 with a slight higher incidence 
in male (Pavlidis et al., 2003).  In Malaysia, CUP accounts for 3.4% of newly diagnosed cancer 
in males and 1.9 % in females (Omar and Tamin, 2011). According to the same report, the 
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highest incidence of CUP was observed in the 65 - 69 age group for males and in the 55 - 59 age 
group for females. CUP is the 9th most common cancer in males and the 13th most common 
cancer in females in Malaysia. The incidence is higher in males (59.4%) compare to female 
(40.6%) with slightly higher preponderance in males of Malay ethnicity (25%) compared to other 
races. 
 
2.3 Clinical and biological characteristics 
Carcinomas of unknown primary tumours share similar clinical and biological characteristics. 
Non-specific complains within a short period of time for example loss of weight and loss of 
appetite are common presentation in patients diagnosed with CUP. The location of the primary 
origin may remain undiscovered during the patient’s existence, even after autopsy only 70-80% 
of primary tumours is reported to been found (Le Chavlier et al. 1988). The similar study also 
noted unusual pattern of metastases, frequently involving the kidneys, adrenal gland, skin and 
heart. Another interesting observation that they made was, even at autopsy there were differences 
in metastatic localization between those of CUP and known primary tumours. Many factors may 
contribute to this elusiveness including its small size and sub mucosal location. Another 
hypothesis is that the angiogenic incompetence of the primary tumor leads to marked apoptosis 
and cell turnover (Naresh, K.N., 2002). CUP can be categorised in to four major subtypes, with 
adenocarcinomas of well or moderate differentiation the most predominantly histological finding 
in 60% of cases (Pavlidis et al 2004). This was followed by undifferentiated or poorly 
differentiated carcinomas (30%), squamous cell carcinoma (5%) and undifferentiated carcinoma 
(5%). 
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2.4 Diagnostic evaluation of carcinoma of unknown primary 
Patients with CUP are often subjected to undergo pathology, biochemistry, imaging and 
endoscopic studies for diagnostic evaluation Adequate tissue sample is needed in order to 
perform light microscopy, immunohistochemistry, IHC and markers/ receptor studies as well as 
more specific investigations such as electron microscopy or genetic analysis. Light microscopic 
examination with staining, may characterise cell morphology and cell differentiation. On light 
microscopy, most CUP cancers are identified as adenocarcinoma (60%) or poorly differentiated 
adenocarcinoma or undifferentiated carcinoma or neoplasm (30%–35%); the remaining lesions 
are squamous cell carcinoma or neuroendocrine cancers (5%) (Varadhachary, G.R., 2007) 
 
Further characterization of the carcinoma can be done with immunohistochemistry, IHC studies. 
IHC stains are peroxidase labelled antibodies against specific tumor antigens that are used to 
define tumor lineage. Meta-analysis of 5 studies by Anderson and Weiss in 2010 showed IHC 
studies correctly identified the tissues in 82.3% (95%, confidence interval 77.4 to 86.3%) when 
both the primary and metastatic tumour were studied together. This being said, the same study 
also found that when the metastatic tumor was studied without knowing the primary tumor, IHC 
studies only correctly identified the tissues in 65.5% (95% confidence interval 60.1-70.7%) of 
cases.  IHC screening is also costly and time consuming, which requires special expertise and 
may not be available in all institutions (Oien & Dennis , 2012). 
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Another method used to identify the primary origin of CUP is by performing molecular profiling 
of the biopsied tissue. This can be performed with minimal tissue biopsy, which is usually the 
case in samples acquired from fine needle biopsies. DNA or RNA (messenger RNA (mRNA) or 
microRNA (miRNA)) microarray or quantitative real-time polymerase-chain-reaction (rt-PCCR) 
assays are often used to ascertain the primary location of the tumor. In these methods, the genes 
from CUP are evaluated and assumptions are made that the molecular signals of the metastatic 
tumours matches their primary origin. Hence by matching molecular signals, the primary tumor 
could be identified. There are currently three mRNA and miRNA methods, which are available 
commercially, used in order to ascertain the origin of the tumor in CUP. The Pathwork Tissue of 
Origin, TOO test is a microarray-based gene expression assay assessment which analyses 2000 
mRNas of the biopsy tissue (Pillai et al 2011). It has a database of 2140 tumor of 58 types and 
subtypes grouped 15 classes which includes bladder, breast, colorectal, gastric, germ cell, 
hepatocellular, kidney, non–small cell lung, non-Hodgkin lymphoma, melanoma, ovarian, 
pancreatic, prostate, soft tissue sarcoma, and thyroid. The ToO test will report on the similarity 
scores, SS comparing the above mentioned 15 tumor classes. The higher the SS, the more likely 
the diagnosis is. BioTheranostic’s Cancer Type ID, (CTID) uses the rt-PCR method to look at 
92mRNas. It has a database, which contains 2206 tumours of 30 main types and 54 subtypes 
(Erlander at al, 2011). Whilst the mIRview mets2 looks at 64miRNas by microarray with a 
dataset which contains 1282 tumours with 42 types and subtypes (Meiri E et al, 2012). Despite 
very high specificity of these three molecular profiling methods, their sensitivity in known origin 
ranges from 72% to 95% and sensitivity is often lower in metastases than in primary tumours 
(Takei et al, 2011). Study done by Pillai et all (2011) found that the TOO test showed 91% 
sensitivity in 179 known metastases and 87% sensitivity in 283 poorly differentiated or 
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undifferentiated primary tumours. CTID showed 83% sensitivity in 187 known primary tumours 
(Erlander et al, 2011). Kerr et al (2012) found that CTID showed sensitivities of 87% for tumor 
typing and 82% for subtyping in 790 known primary and metastatic cancers in an independent 
study. Meiri at al (2012) showed that mirView mets2 showed 85% sensitivity in 509 known 
primary and metastatic tumours. However, when applied to CUP, the ToO test generated a 
prediction in 96% of 45 samples, which was found clinically appropriate (Hainsworth et al, 
2011). Meanwhile, CTID yielded a prediction in 91% of 815 submitted cancers of indeterminate 
or unknown primary (Schroeder et al, 2012). In another study by Greco at al (2010), CTID 
provided 20 predictions in patients of CUP patients whom the primary site became unknown. 
According to the same study, 75% of the predictions were correct, 10% were indeterminate and 
15% appeared incorrect. miRview mets2 agreed with clinic-pathological data in 88% of 55 brain 
CUPs (Meiri et al 2012) and in another study of 84 CUP patients, the test agreed in 92% of 84 
assessable cases (Pentheroudakis et al, 2013). However, there are limits to what molecular 
profiling has to offer. The ToO test for example, as its result is reported as one of 15 classes, the 
tumor subtype at a given site does not appear to be described and also the classes lacks certain 
tumor types which include neuroendocrine tumours, cholangiocarcinoma and mesothelioma 
(Pillai et al, 2011). In all three tests, common incorrect diagnoses include pancreatic, colonic and 
gastroesophageal cancer (Greco et al 2010 and Kerr et al 2012). Added to the above-mentioned 
problems with molecular profiling, the mentioned commercially available kits are very costly. 
ToO testing costs between 3000 and 4000 US dollars, or roughly 10 to 20 times the cost of 
immunohistochemistry (Oien & Dennis, 2012) 
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Routine use of serum tumor marker is not recommended as it has not been proven to be of 
prognostic value and will not assist in the diagnosis of the origin of the primary site. This was 
attributed to over expression of tumor markers in patients with CUP (Milovic et al. 2002). 
However, there is serum markers recommended for different subgroups of patients which has 
found to be of benefit. Serum markers recommended for males presenting with CUP are serum 
ß-HCG, AFP and PSA to exclude treatable extra-gonadal germ cell tumours and identify 
metastatic prostate carcinoma amendable to endocrine treatment (Pavlidis et al. 2003). Serum 
thyroglobulin is also recommended in patients presenting with bone metastases to rule out 
thyroid carcinoma. Serum Ca 15-3 and Ca 125 are said to be useful in patients presenting with 
axillary node adenocarcinomas and in peritoneal papillary adenocarcinomatosis (Milovic et al. 
2002) 
 
The choice of imaging investigations performed is based on the clinical presentation of these 
patients. It is said that the primary tumours are detected by conventional imaging (Nanni et al. 
2005) in up to 27% of cases. Ultrasound is a quick, easy, involves no radiation and can be done 
at the patients’ bedside. It is nevertheless, operator dependent causing variation in findings. 
Chest x-ray is very simple and routinely done. However, a cross sectional whole body imaging is 
desired as the primary site of the tumor can be anywhere in the body. Computed Tomography, 
CT scan is another imaging modality that is routinely performed to assist in the diagnosis. Chest, 
abdominal and pelvic CT scan may be performed depending on the clinical presentation of 
patients. Not only CT scan may help detect the primary tumor site, it can also assess the stage of 
the disease and at the same setting locate the site that can be biopsied. CT of the abdomen and 
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pelvis results in the detection of a primary site for the cancer in 30–35% of patients (Karsell et al. 
1982). Female patient who presents with metastatic adenocarcinoma and clinical presentation 
suggestive of breast carcinoma may undergo ultrasound of the breast and mammogram. MRI 
breast can also be utilized in these patients if ultrasound and mammogram shows negative results 
(Olson et al., 2000). However, CT and MRI can miss small lesion or pathological changes in 
normally sized tissues especially in CUP cases where the primary tumours are said to be small 
(Pavlidis 2007). 
 
Endoscopic investigations are used to evaluate patients with specific clinical presentation. It is 
recommended that patients presenting with solitary cervical node to have ENT endoscopy, 
patients with thoracic indications or pulmonary symptoms should undergo fibre optic 
bronchoscopy, patients with abdominal symptoms or with positive faecal occult blood test 
should have gastrointestinal endoscopies in and patients with inguinal lymph node involvement 
should have proctoscopy and/ or colposcopy (Fizazi et al 2015 & Casciato et al., 1990). 
 
2.5 Treatment of carcinoma of unknown primary 
Besides than identifying the location of the primary, patients can also be classified into 
favourable and unfavourable subsets. This is done based on clinical and pathology criteria, 
whereby patients with CUP can be divided into favourable and unfavourable prognosis (Palvadis 
et al 2003). Favourable prognosis includes women with peritoneal carcinomatosis, women with 
isolated axillary lymph node metastases, adenocarcinoma presenting as single metastatic lesion, 
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young men with features of extra gonadal germ cell tumor, squamous cell involving the cervical 
or inguinal lymph nodes and neuroendocrine carcinoma (Hainworth JD and Fizazi K, 2009). 
This being said, only 15-20% of patients fall into the favourable prognosis and the majority will 
fall into the unfavourable prognosis. The unfavourable prognosis patients, unlike the favourable 
prognosis patients do not have tumours that are chemo sensitive and may not experience long-
term disease control. Despite management with a variety of chemotherapeutic combination, 
patients with unfavourable prognosis (especially those with poor performance status and 
abnormal serum lactate dehydrogenase) have poor prognosis (Golfinopoulos et al 2009).  
 
Systemic chemotherapy is the main treatment modality for most patients, but surgery, radiation 
therapy, and even periods of observation are important. The regimes, which are recommended 
based on thorough evaluation, are the combination of taxane/ platinum or gemcitabine/ platinum. 
The response rate is said to be 30 to 40% with median survivals of 8 to 11 months (Culine et al, 
2003 & Hubner et al, 2009).  
 
2.6 Carcinoma of unknown primary and F-18 FDG PET  
As previously mentioned, one of the characteristic of CUP is its early dissemination and its 
aggressiveness. Primary tumours with metastatic ability, most often have increased glucose 
metabolism due to its rapid growth. F-18 Flurodeoxyglucose, FDG is a radioactive glucose 
analogue which unlike conventional radiology, looks at the tissue metabolism. It will be taken up 
by cells by facilitated passive diffusion through the glucose transporters, GLUT and 
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phosphorylated by hexokinase intracellularly. Once entering the cells, F-18 FDG will be trapped, 
as it will not be metabolized like normal glucose. There are 5 subtypes of GLUT (GLUT-1 to 
GLUT-5) and of these; GLUT-1 is found to be over expressed in tumor cells. Hexokinase is also 
over expressed causing higher F-18 FDG trapping in the tumor cell. F18-FDG will undergo 
spontaneous decay and emit positron particles which will be annihilated by electrons to produce 
two photons with the energy of 511keV directed 180° apart. These photons will be detected by 
the crystals of the PET camera, resulting in images representing the bio distribution of F-18 
FDG. 
 
Since the introduction of FDG and Positron Emission Tomography, PET several studies have 
been carried out to evaluate the role of FDG PET in the detection of primary location of the 
tumor in patients diagnosed with CUP. Delgado et al. (2003) performed a meta-analysis, which 
showed that the primary tumor was identified in 43% of patients with CUP referred for FDG 
PET study. The same study also found sensitivity and specificity of F-18 FDG PET in detection 
of the primary site was 87% and 71%. Another systemic review done by Sève et al. (2006) found 
that F-18 FDG detected the primary tumor in 41% of patients diagnosed with CUP and that F-18 
FDG changed the oncology management in approximately one-third of the patients in the 
studies. The role of F-18 FDG PET has been established in management of metastatic squamous 
carcinoma of the cervical nodes. The primary tumor was ascertained in one third of patients 
diagnosed with CUP, presenting with this histology from biopsy of the cervical node 
(Bohuslavizki et al. 2000). In addition, its also found that F-18 FDG PET might influence the 
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treatment for patients in this group with localized node involvement, which will be considered 
for local treatment (external beam radiotherapy) instead of systemic chemotherapy. 
 
2.7 Carcinoma of unknown primary and F-18 FDG PET-CT 
Similar to any other diagnostic tool, FDG PET is not without its limitation. One of the problems 
encountered previously was localization of lesion seen on imaging, as the spatial resolution of 
PET camera detectors was very poor, it may contribute to false negative result. With the 
introduction of hybrid imaging, which uses CT scan to correctly locate the lesion with high FDG 
uptake, localization of lesions improved  (Keller et al 2011) from 31% to 55%. Hence, hybrid 
imaging or PET-CT is now the standard current practise rather than PET alone. In a study by 
Pelosi et al 2006, the primary tumor site was detected in correctly identified in 24 out of 68 
patients (35.3%). In the similar study (Pelosi et al 2006) also showed that the identification rate 
of the primary site is higher in the presence of adenocarcinoma compared to carcinoma histotype 
and that FDG PET-CT influenced the treatment instituted by oncology team in almost 50% of 
the cases. Other causes of false negative result are tumor with low metabolic rate and tumor with 
known lower avidity for FDG. False positive findings in PET-CT utilising FDG are commonly 
seen in infection, when there is increased utilization of glucose by granulocytes and monocytes 
during their metabolic burst. Inflammation, high physiological glucose uptake in normal tissue 
and regions of discrete uptake can also contribute to false positive results.  
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CHAPTER THREE 
OBJECTIVES AND HYPOTHESIS 
 
3.1 General Objective 
To investigate the role of Positron Emission Tomography with Computed Tomography, 
PET-CT using F-18 Flurodeoxyglucose, FDG in detection of Carcinoma of Unknown 
Primary in Malaysia. 
 
3.2 Specific objective 
1. To identify the relationship between metastatic biopsy (metastatic adenocarcinoma 
and metastatic carcinoma) histopathology and identification rate of the primary 
tumour. 
2. To identify the relationship between metastatic location (cervical and extra cervical) 
and identification rate of the primary tumour. 
3. To evaluate the identification rate of primary tumour in patients with carcinoma of 
unknown primary with PET-CT using F-18 FDG. 
4. To calculate the sensitivity, specificity and positive predictive value of F-18 FDG 
PET-CT in detecting the primary tumour sites of patients diagnosed with carcinoma 
of unknown primary. 
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3.3 Research hypothesis 
1. There is a difference between identification rates of metastatic adenocarcinoma and 
metastatic carcinoma 
2. There is a difference between identification rates of cervical and extra cervical 
metastases. 
 
3.4 Null hypothesis 
1. There is no difference between identification of primary tumour rates of metastatic 
adenocarcinoma and metastatic carcinoma 
2. There is no difference between identification rates of cervical and extra cervical 
metastases. 
 
3.5 Rationale of study 
In Malaysia, PET-CT using F-18 FDG has been used as a diagnostic tool to search for primary 
site for CUP when other modalities fail. There is so far no study done to assess the role of PET-
CT in detection of CUP in Malaysia. PET-CT not only has show to play a role in diagnosis of 
carcinoma of unknown primary, it can also be used to assess for distant metastasis hence can 
contribute towards the management of patients diagnosed with CUP. 
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3.5 Benefits of the study 
1. Benefit to patient as early diagnosis of primary site, limits unnecessary investigation, 
hence saves time and cost.  
 
2. Benefit to physician as tailored treatment can be instituted to patient as soon as 
possible, changes prognosis and can be used to assess treatment in patients.  
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CHAPTER FOUR 
METHODOLOGY 
 
4.1 Subjects and material 
This is a retrospective study, which was carried out in the Department of Nuclear Medicine, 
National Cancer Institute, Putrajaya, Malaysia. The subjects are patients who were referred from 
other tertiary hospitals from all over Malaysia. Patients who were included in this study are those 
who met the following inclusion criteria: (1) Positive histology findings from metastases from 
unknown primary site. (2) Patients who have undergone a thorough diagnostic evaluation by the 
referring team which included radiological and IHC investigation. (3) No prior anti-cancer 
treatment done. (4) No history of previous malignancy. The standard operative procedures of the 
department were used to conduct the PET-CT acquisition. Data collection was carried out from 
the FDG PET/CT database and patient’s medical records, and then stored in a secured computer. 
Ethical clearance from Medical Research and Ethics Committee (MREC) Malaysia as well as 
Jawatankuasa Etika Penyelidikan (Manusia) JEPeM, USM were obtained prior to the 
commencement of this study. This study was carried out according to the Declaration of 
Helsinki. Informed consent was waived due to the retrospective design of this study.  
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ALL PATIENTS DIAGNOSED WITH CUP AND UNDERWENT 
FDG PET/CT IN HOSPITAL PUTRAJAYA 
POSITIVE RESULT OF FDG PET/CT FOR 
PRIMARY 
NEGATIVE RESULT OF FDG PET/CT FOR 
PRIMARY 
INCLUSION CRITERIA: 
(1) Positive histology findings 
from metastases. (2) Patients 
who have undergone a 
thorough diagnostic 
evaluation. (3) No prior anti-
cancer treatment done. (4) No 
history of previous malignancy 
TRUE POSITIVE 
RESULT AFTER 
SURGERY/ BIOPSY 
FALSE POSITIVE 
RESULT AFTER 
SURGERY/ BIOPSY 
FALSE NEGATIVE RESULTS 
AFTER FDG PET/CT AND 
DURING FOLLOW-UP 
TRUE NEGATIVE RESULTS 
AFTER FDG PET/CT AND 
DURING FOLLOW-UP 
Figure 4.1: Flow chart of study protocol. 
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4.2 F-18 FDG PET-CT Imaging 
Patients were advised to fast for at least 6 hours and abstain from strenuous exercise for 24 hours 
prior to the PET-CT appointment day. Capillary blood was used to assess fasting glucose levels. 
The preferred glucose level was < 8.3mmol/L, if exceeded, subcutaneous insulin was 
administered. F-18 FDG injections were only given 2 hours after administration of subcutaneous 
insulin. If the fasting glucose level exceeded 11.0mmol/L, the PET-CT will be differed and 
patients were referred back for glucose control. Patients with fasting glucose level of 
11.0mmol/L and bellow received 5MBq/kg of F-18 FDG, which was administered intravenously 
by experienced nurses who are trained to deliver F-18 FDG. This was followed by 45 minutes to 
1 hour of resting in an ambiance room. Imaging was carried out without intravenous or oral CT 
contrast after 45 minutes to 1 hour of FDG injection. 
 
An integrated PET-CT system (Discovery ST, GE Medical System, Milwaukee, USA) was used 
for all the patients who underwent the F-18 FDG PET-CT for this study. The image acquisition 
was started with CT scan from the head to the mid-thigh region (60mA, 140kV, tube-rotation 
time of 0.8 second per rotation) during current breathing. Immediately followed by PET (two-
dimensional) from the head to the mid-thighs as well (4 minutes emission scan per table position, 
3.3mm slice thickness with 7 fields of view and 15cm per field). Filtered back-projection and 
ordered-subset expectation-maximization (OS-EM) (two iterations, 15 subsets and matrix of 
128×128) were used to reconstruct the PET data with and without CT attenuation correction. A 
dedicated workstation running Advantage version 4.2 software (GE Medical System, 
Milwaukee, USA) was used to display the attenuation corrected PET, CT and combined PET-CT 
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images. The results were reviewed by two experienced nuclear medicine physicians sequentially 
and consensus reporting was made. Two methods applied, which were visual assessment and 
semi quantitative measurement of FDG uptake using maximum standardized uptake values 
(SUVmax) to interpret the PET-CT scans. 
 
The final result was confirmed with analysis of histologic confirmative examination and/or 
formal clinical follow-up findings were served as the reference standard. Formal clinical follow-
up includes physical examination and radiological imaging. FDG PET-CT positive results were 
defined as true positive, TP when confirmed by the reference standard and as false positive, FP 
when the reference standard revealed no evidence of PET-CT results. True negative is defined by 
negative FDG PET-CT and confirmed by the reference standard, false negative, FN when there 
was subsequent proof of malignancy by the reference standard despite negative FDG PET-CT. 
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4.3 Statistical Analysis 
Statistical analysis was performed using SPSS Version 22.0 to assess whether there was 
correlations between findings of the PET-CT scan with the tumour histopathology examination 
and between PET-CT findings with groups of patients with cervical and extra cervical lymph 
node metastases. The p-values less than 0.05 were considered statistically significant. Sensitivity, 
specificity and positive predictive values were calculated using standard statistical formula. 
Formula for calculating diagnostic FDG PET-CT in detecting primary tumor were as follow: 
sensitivity = TP/(TP+FN), specificity = TN/(TN+FP), positive predictive value, PPV = 
TP/(TP+FP) 
. 
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CHAPTER FIVE 
RESULTS 
5.1 Patient Demographics 
A total of 112 patients were diagnosed with CUP and underwent FDG PET-CT from 1st July 
2013 and 31st December 2014. However, only 70 patients fulfilled the inclusion criteria of this 
study and were recruited. Thirty-one patients (44.3%) were male and the remaining thirty-nine 
(55.7%) were female, giving the male to female ratio of 1:1.8. The median age of the study 
sample was 56 years old (SD 14.11). Half of the study samples were Malay, followed by Chinese 
and Indian with 32.9% and 17.1 % respectively (TABLE 5.1). 
 
42 out of 70 (60%) patients enrolled, had biopsy, which showed carcinoma histopathology (20 
metastatic carcinoma, 9 poorly differentiated carcinoma, 8 metastatic squamous carcinoma, 3 
metastatic papillary carcinoma and 2 undifferentiated carcinoma), 26 (37.1%) showed 
adenocarcinoma and 2 (2.9%) showed melanoma histopathology. Median follow up duration was 
6 months (range 3-12 months). 
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TABLE 5.1: The demographic characteristics of study samples and the distribution of 
disease by HPE results. 
Characteristics Number of sample 
(n) 
Percentage 
(%) 
Gender:    
Male 31 44.3 
Female  39 55.7 
Race:   
Malay 35 50.0 
Chinese 23 32.0 
Indian 12 17.1 
Others 0 0 
Age:   
Min 15 y.o  
Max 83 y.o  
Median age 56 y.o  
SD 14.11  
Histopathology result (HPE):   
Metastatic adenocarcinoma 26 37.1 
Metastatic carcinoma 42 60.0 
Malignant melanoma 2 2.9 
 
 
 
